Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Generated: June 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020235

« Back to Dashboard

NDA 020235 describes NEURONTIN, which is a drug marketed by Pfizer Pharms and Parke Davis and is included in three NDAs. It is available from two suppliers. There is one patent protecting this drug. Additional details are available on the NEURONTIN profile page.

The generic ingredient in NEURONTIN is gabapentin. There are twenty-eight drug master file entries for this compound. One hundred and ten suppliers are listed for this compound. Additional details are available on the gabapentin profile page.

Summary for 020235

Tradename:	NEURONTIN
Applicant:	Pfizer Pharms
Ingredient:	gabapentin
Patents:	0
Therapeutic Class:	Anticonvulsants
Formulation / Manufacturing:	see details

Pharmacology for NDA: 020235

Physiological Effect	Decreased Central Nervous System Disorganized Electrical Activity

Suppliers and Packaging for NDA: 020235

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
NEURONTIN	gabapentin	CAPSULE;ORAL	020235	NDA	Parke-Davis Div of Pfizer Inc	0071-0803	N	0071-0803-24
NEURONTIN	gabapentin	CAPSULE;ORAL	020235	NDA	Parke-Davis Div of Pfizer Inc	0071-0805	N	0071-0805-24

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	CAPSULE;ORAL			Strength	100MG
Approval Date:	Dec 30, 1993	TE:	AB	RLD:	Yes

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	CAPSULE;ORAL			Strength	300MG
Approval Date:	Dec 30, 1993	TE:	AB	RLD:	Yes

Profile for product number 003

Active Rx/OTC/Discontinued:	RX	Dosage:	CAPSULE;ORAL			Strength	400MG
Approval Date:	Dec 30, 1993	TE:	AB	RLD:	Yes

Expired US Patents for NDA 020235

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer Pharms	NEURONTIN	gabapentin	CAPSULE;ORAL	020235-001	Dec 30, 1993	➤ Sign Up	➤ Sign Up
Pfizer Pharms	NEURONTIN	gabapentin	CAPSULE;ORAL	020235-002	Dec 30, 1993	➤ Sign Up	➤ Sign Up
Pfizer Pharms	NEURONTIN	gabapentin	CAPSULE;ORAL	020235-002	Dec 30, 1993	➤ Sign Up	➤ Sign Up
Pfizer Pharms	NEURONTIN	gabapentin	CAPSULE;ORAL	020235-001	Dec 30, 1993	➤ Sign Up	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.